Targovax granted European Patent for ONCOS-102 in combination with checkpoint inhibitors

OSLO, Norway, Oct. 12, 2020 /PRNewswire/ -- Targovax ASA ("Targovax" or "the Company") (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announce that the European Patent Office has granted European Patent no 3293201. The patent covers the use of ONCOS-102 in combination with checkpoint inhibitors.

Torbjørn Furuseth, Chief Financial Officer of Targovax, said: "We are delighted that this European patent has been granted, further strengthening Targovax's intellectual property portfolio covering the very important combination of ONCOS-102 and anti-PD1 checkpoint inhibitors. The oncology market is ever expanding, with the immuno-oncology segment expected to see the largest growth in the coming years. Securing this patent protects our innovative oncolytic immunotherapy platform and strengthens our market position."

In 2019 Targovax reported encouraging data from part 1 of a trial in PD-1 checkpoint refractory melanoma. This trial examines how ONCOS-102 reactivates the immune system of patients that have progressed on checkpoint inhibitor treatment. The aim is to trigger relevant T-cell production and infiltration into the tumor so that patients who have become refractory can benefit from retreatment with the checkpoint inhibitor. Data from part 2 of this trial is expected later in 2020.

Targovax's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. ONCOS-102 is currently being tested in mesothelioma, melanoma ovarian and colorectal cancers and has already shown promising clinical results both as monotherapy and in combination with chemotherapy, and checkpoint inhibitors.

CONTACT:

For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47-922-61-624
Email: renate.birkeli@targovax.com

Media and IR enquires:
Andreas Tinglum
Corporate Communications (Norway)
Phone: +47-9300-1773
Email: andreas.tinglum@corpcom.no

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/targovax/r/targovax-granted-european-patent-for-oncos-102-in-combination-with-checkpoint-inhibitors,c3214022

View original content:http://www.prnewswire.com/news-releases/targovax-granted-european-patent-for-oncos-102-in-combination-with-checkpoint-inhibitors-301149960.html

SOURCE Targovax


Company Codes: Bloomberg:TRVX@NO, Frankfurt:TA5, ISIN:NO0010689326, LSE:0RIS, Oslo:TRVX, RICS:TRVX.OL, Stockholm:TRVXO, Munich:TA5, Stuttgart:TA5

Back to news